MaaT Pharma S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAAT.PA research report →
About the company
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation.
- CEO
- Herve Affagard
- IPO
- 2021
- Employees
- 59
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $43.81M
- P/E
- -1.41
- P/S
- 9.68
- P/B
- 25.68
- EV/EBITDA
- -1.19
- Div Yield
- 0.00%
- Gross Margin
- 49.89%
- Op Margin
- -699.73%
- Net Margin
- -686.58%
- ROE
- -615.43%
- ROIC
- -100.44%
- Revenue
- $4.52M · 40.67%
- Net Income
- $-31,061,000 · -7.46%
- EPS
- $-1.95 · 11.36%
- Op Income
- $-34,150,000
- FCF YoY
- 27.52%
- 52W High
- $8.62
- 52W Low
- $2.60
- 50D MA
- $4.60
- 200D MA
- $5.12
- Beta
- 0.38
- Avg Volume
- 103.49K
Get TickerSpark's AI analysis on MAAT.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MAAT.PA coverage
Recent articles, reports, and earnings notes.
No research on MAAT.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAAT.PA report →Similar companies
Peers in the same neighborhood.